Dupilumab efficacy in uncontrolled, moderate-to-serve allergic asthma in the phase 3 liberty asthma quest study

Παρόμοια τεκμήρια

• Dupilumab reduces severe exacerbation rate and improves lung function in adolescent patients with uncontrolled, moderate-to-severe asthma: from the Liberty Asthma Quest study
  ανά: Maspero, J, κ.ά.
  Έκδοση: (2018)
• A randomized, controlled phase 3 study, Liberty Asthma Quest, evaluating the efficacy and safety of dupilumab in uncontrolled moderate-to-severe asthma
  ανά: Castro, M, κ.ά.
  Έκδοση: (2018)
• Dupilumab reduces risk of severe exacerbations and improves FEV1 in patients on both high- and medium dose ICS with uncontrolled, moderate-to-severe asthma from the phase 3 LIBERTY ASTHMA QUEST Study
  ανά: Pavord, I, κ.ά.
  Έκδοση: (2018)
• Type 2 biomarkers associated with dupilumab efficacy in patients with uncontrolled, moderate-to-severe asthma enrolled in the phase 3 study LIBERTY ASTHMA QUEST
  ανά: Wenzel, SE, κ.ά.
  Έκδοση: (2018)
• Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
  ανά: Mario Castro, κ.ά.
  Έκδοση: (2020-01-01)